It is unclear who the firms are and the company is most likely to attract interest from lower mid-market firms, said PeHUB, citing two sources.
Since being acquired by Tailwind, VersaPharm has seen its EBITDA grow to $50m from $8m. The firm is looking to sell the company for eight to ten times its EBITDA, said the sources.
VewrsaPharm is focused on developing treatments for tuberculosis and other infectious diseases.
Tailwind is currently raising its second fund, which has a $750m target. The fund did not have any commitments as at last October, regulatory filings showed.
Copyright © 2014 AltAssets